Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Current Assets (2020 - 2025)

Cytek Biosciences' Current Assets history spans 6 years, with the latest figure at $392.0 million for Q4 2025.

  • For Q4 2025, Current Assets fell 1.12% year-over-year to $392.0 million; the TTM value through Dec 2025 reached $392.0 million, down 1.12%, while the annual FY2025 figure was $392.0 million, 1.12% down from the prior year.
  • Current Assets reached $392.0 million in Q4 2025 per CTKB's latest filing, up from $388.5 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $454.0 million in Q4 2022 to a low of $216.9 million in Q2 2021.
  • Average Current Assets over 5 years is $401.9 million, with a median of $396.4 million recorded in 2024.
  • Peak YoY movement for Current Assets: skyrocketed 106.95% in 2021, then fell 13.65% in 2023.
  • A 5-year view of Current Assets shows it stood at $431.7 million in 2021, then increased by 5.16% to $454.0 million in 2022, then fell by 13.65% to $392.1 million in 2023, then increased by 1.12% to $396.4 million in 2024, then dropped by 1.12% to $392.0 million in 2025.
  • Per Business Quant, the three most recent readings for CTKB's Current Assets are $392.0 million (Q4 2025), $388.5 million (Q3 2025), and $382.8 million (Q2 2025).